{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-25-000059","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.793737+00:00","generated_at":"2026-05-17T01:14:07.042464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Edwards Q3 sales rise 14.7% to $1.55B; raises FY EPS guidance to $2.56-$2.62","bullets":["Q3 sales $1.55B (+14.7% YoY); adjusted EPS $0.67 vs $0.50 GAAP.","TAVR sales $1.15B (+12.4%); TMTT sales $145.2M (+59.3%).","Raised FY2025 adjusted EPS guidance to $2.56-$2.62 from high end of $2.45-$2.55.","Raised TAVR sales growth guidance to 7-8% from 6-7%; total sales growth to high end of 9-10%.","Board increased share repurchase authorization to $2.1B."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-25-000059","json":"https://secwatch.observer/filing/0001099800-25-000059.json","markdown":"https://secwatch.observer/filing/0001099800-25-000059.md","text":"https://secwatch.observer/filing/0001099800-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980025000059/0001099800-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980025000059/ew-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:14:07.042464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}